Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 November 2023 | Story Valentino Ndaba | Photo SUPPLIED
UFS KovsieCare GBV Social Media
The UFS is joining forces with the international community during the annual 16 Days of Activism against Gender-Based Violence.

As the world will soon commemorate the 16 Days of Activism against Gender-Based Violence (GBV) campaign, the University of the Free State (UFS) joins the fight against this pervasive issue. Dedicated to eradicating GBV and fostering a safe environment, the institution has pledged an unwavering commitment to a zero-tolerance stance against all forms of GBV.

The 16 Days of Activism against Gender-Based Violence is an annual global initiative that starts on 25 November 2023 – International Day for the Elimination of Violence against Women – and concludes on 10 December 2023 – Human Rights Day. The theme for this year, ‘Accelerating actions to end gender-based violence and femicide: leaving no one behind’, emphasises the need for a comprehensive, inclusive effort to combat GBV. 

Legislation addressing GBV

Gender-based violence, rooted in the systemic imbalance of power and authority, manifests in multifaceted forms that encompass emotional, physical, financial, and sexual abuse, among others. Recognising the gravity of this issue, parliament has enacted laws, including the Domestic Violence Act of 1998 and the Children's Act of 2005, striving to safeguard individuals from such atrocities and championing fundamental human rights.

The UFS, aligned with parliament's vision and encapsulating its own Vision 130 within the 2023-2028 Strategic Plan, remains steadfast in its dedication to fostering a culture of accountability, care, and social justice within its staff and student community. 

The significance of activism

Dr Lentsu Nchabeleng, Deputy Director in the Gender Equality and Anti-Discrimination Office (GEADO), emphasised the pivotal role of the 16 Days of Activism in societal progress. “Advocacy plays an important role in prevention by promoting education and awareness. Advocacy challenges harmful societal norms and stereotypes that contribute to gender-based violence and can help foster a culture of equality and respect," she stated.

Useful resources

The UFS has provided resources for the staff and student community, including frequently asked questions (FAQs) about GBV and sexual offences, aiming to clarify these important matters. Help and reporting avenues for GBV and sexual misconduct are available on the Bloemfontein and South campuses, with similar support available on the Qwaqwa Campus, underscoring the university's dedication to a safe and supportive environment for all. 

Click to download the resource documents:

Important contacts 

The university has also implemented support systems, including dedicated 24-hour toll-free helplines for reporting GBV and sexual offenses, underscoring its commitment to addressing this epidemic.

  • GEADO toll-free: 0800 204 682
  • UFS Student Careline toll-free: 0800 00 6363

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept